Agios
Pharmaceuticals Inc. (Nasdaq: AGIO) reported positive interim data from a
Phase 1 study of AG-120 in treating patients with acute myeloid
leukemia.Shares of the biopharmaceutical leaped $12.16 to close at $95.97.
Positive interim results for Agios Pharmaceuticals
November 19, 2014 at 16:41 PM EST